Diagnosis of lymphoid malignancies and minimal residual disease detection

• US 9,824,179 B2
• Filed: 12/07/2012
• Issued: 11/21/2017
• Est. Priority Date: 12/09/2011
• Status: Active Grant

• Current Assignee: Adaptive Biotechnologies Corp.
• Original Assignee: Adaptive Biotechnologies Corp., Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Inventors: Sherwood, Anna M., Robins, Harlan S.
• Primary Examiner(s): Skibinsky, Anna
• Application Number:
  US13/708,847
• Publication Number:
  US 20130253842A1
• Time in Patent Office: 1,810 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids

Abstract

Methods are described for diagnosis of a lymphoid hematological malignancy in a subject prior to treatment, and for detecting minimal residual disease (MRD) in the subject after treatment for the malignancy, by high throughput quantitative sequencing (HTS) of multiple unique adaptive immune receptor (TCR or Ig) encoding DNA molecules that have been amplified from DNA isolated from blood samples or other lymphoid cell-containing samples. Amplification employs oligonucleotide primer sets designed to amplify CDR3-encoding sequences within substantially all possible human VDJ or VJ combinations. Disease-characteristic adaptive immune receptor clonotypes occur, prior to treatment, at a relative frequency of at least 15-30% of rearranged receptor CDR3-encoding gene regions. Following treatment, persistence of at least one such clonotype at a detectable frequency of at least 10⁻⁶ or at least 10⁻⁵ receptor CDR3-encoding regions indicates MRD. Improved quantitative embodiments are provided by inclusion of a template composition for amplification factor determination and related methods.

Claims

1. A method of quantifying the number of input molecules for one or more rearranged DNA sequences identified as indicative of a clonal lymphoid hematological malignancy, comprising:

(A) amplifying by a single multiplex polymerase chain reaction (PCR);

(i) a plurality of gene segments from a sample comprising T cells and/or B cells to produce a plurality of sample amplicons, wherein each gene segment comprises rearranged TCRβ

CDR3-encoding region or a rearranged Ig CDR3-encoding region comprising a variable (V)-region and a joining (J)-region, and wherein said single multiplex PCR amplifies substantially all rearranged TCRβ

CDR3-encoding regions or substantially all rearranged Ig CDR3-encoding regions; and

within the single multiplex PCR

(ii) a known number of a plurality of template oligonucleotides each having a unique oligonucleotide sequence to produce a plurality of template amplicons wherein each of said template oligonucleotides is defined by the formula;

5′

-U1-B1-V-B2-R-B3-J-B4-U2-3′

wherein V comprises a polynucleotide comprising at least 20 and not more than 1000 contiguous nucleotides of a V-region encoding gene segment or a complement thereof, and wherein V comprises a unique oligonucleotide sequence;

wherein J is a polynucleotide comprising at least 15 and not more than 600 contiguous nucleotides of a J-region encoding gene sequence, or a complement thereof, and wherein J comprises a unique oligonucleotide sequence;

wherein U1 comprises an oligonucleotide having a sequence that is selected from (i) a first universal adaptor oligonucleotide sequence, and (ii) a first sequencing platform-specific oligonucleotide sequence that is linked to and positioned 5′

to a first universal adaptor oligonucleotide sequence;

wherein U2 comprises an oligonucleotide having a sequence that is selected from (i) a second universal adaptor oligonucleotide sequence and (ii) a second sequencing platform-specific oligonucleotide sequence that is linked to and positioned 5′

to a second universal adaptor oligonucleotide sequence;

wherein B1, B2, B3 and B4 are each independently nothing or each comprises an oligonucleotide barcode sequence, wherein each of the plurality of oligonucleotide barcode sequences comprises a unique oligonucleotide sequence that uniquely identifies, as a paired combination, a unique V oligonucleotide sequence and a unique J oligonucleotide sequence, and

wherein R is either nothing or comprises a restriction enzyme recognition site that comprises an oligonucleotide sequence not found in the template oligonucleotide;

(B) sequencing by high throughput sequencing said plurality of sample amplicons and template amplicons to generate sequence reads of said substantially all rearranged TCRβ

or Ig CDR3-encoding regions and said unique template oligonucleotides;

(C) counting the number of sequence reads of each unique template oligonucleotide and the number of sequence reads of each rearranged TCRβ

or Ig CDR3-encoding region from the sequence reads obtained in step (B);

(D) identifying from the sequence reads of the rearranged TCRβ

or Ig CDR3-encoding regions at least one rearranged TCRβ

or Ig CDR3-encoding region indicative of a clonal lymphoid hematological malignancy in the sample based on the frequency of the sequence reads of the rearranged TCRβ

or Ig CDR3-encoding region as compared to the remaining sequence reads;

(E) calculating an amplification factor by dividing the number of template oligonucleotides counted in (C) by the known number of each of the plurality of template oligonucleotides having a unique oligonucleotide sequence in the template composition amplified in (A)(ii); and

(F) dividing the number of sequence reads counted for the at least one rearranged TCRβ

or Ig CDR3-encoding regions indicative of a clonal lymphoid hematological malignancy identified in (D) and counted in (C) by the amplification factor calculated in (E) thereby quantifying the number of input molecules of one or more rearranged DNA sequences identified as indicative of a clonal lymphoid hematological malignancy.

2. The method of claim 1, wherein said clonal lymphoid hematological malignancy is selected from:

acute T-cell lymphoblastic leukemia (T-ALL), acute B-cell lymphoblastic leukemia (B-ALL), multiple myeloma, plasmacytoma, macroglobulinemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), Hodgkins lymphoma, non-Hodgkins lymphoma, cutaneous T-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, hairy cell leukemia, T prolymphocytic lymphoma, angioimmunoblastic T-cell lymphoma, T lymphoblastic leukemia/lymphoma, peripheral T-cell lymphoma, adult T cell leukemia/lymphoma, mycosis fungoides, Sezary syndrome, T lymphoblastic leukemia, myeloproliferative neoplasm, and myelodysplastic syndrome.

3. The method of claim 1, wherein said rearranged Ig CDR3-encoding regions are selected from a rearranged IgH CDR3-encoding, region (V-D-J), a partially rearranged IgH CDR3-encoding region (D-J), a rearranged IgK CDR3-encoding region, a deleted IgK rearrangement using the iRSS in lieu of a V segment, a deleted IgK rearrangement using the Kdel in lieu of a J segment, or a rearranged Igλ

CDR3-encoding region.

4. The method of claim 3, wherein said rearranged Igκ

CDR3-encoding regions comprise a non-coding iRSS sequence and a joining (1) gene segment rearrangement, or a non-coding variable (V) gene segment and the non-coding Kdel element.

5. The method of claim 1 wherein each of said template oligonucleotides comprises at least one unique barcode sequence.

6. The method of claim 5 wherein each of said template oligonucleotides comprises a V region encoding gene sequence or a complement thereof and J region encoding gene sequence or a complement thereof.

7. The method of claim 6 wherein said unique oligonucleotide barcode sequence comprises a random polynucleotide sequence of at least 6 nucleotides.

8. The method of claim 6 wherein each of said plurality of said template oligonucleotides is present in a substantially equimolar amount.

9. The method of claim 6 wherein each of said plurality of said template oligonucleotides has substantially identical lengths.

10. The method of claim 6 wherein each of said V region encoding gene sequences or a complement thereof is unique to a single V region encoding gene and wherein each of said J region encoding gene sequences or a complement thereof is unique to a single J region encoding gene.

11. The method of claim 1, wherein said at least one unique rearranged sequence identified as indicative of a clonal lymphoid hematological malignancy in said subject is identified from a sample obtained from said subject at a time prior to a treatment.

12. The method of claim 1 wherein said sample comprises at least 100,000 T cells or B cells.

13. The method of claim 1 wherein each of said plurality of template oligonucleotides comprises at least one oligonucleotide barcode that is 3-25 contiguous nucleotides in length.

14. The method of claim 1 wherein at least one rearranged TCRβ

or Ig CDR3-encoding region is identified as being indicative of a hematological malignancy when it has a relative frequency of at least 15% of the total TCRβ

or Ig CDR3-encoding regions counted in step (C).

15. The method of claim 1 wherein at least one rearranged TCRβ

or Ig CDR3-encoding region is identified as being indicative of a hematological malignancy when it has a relative frequency of at least one in 10⁵ of the total TCRβ

of Ig CDR3-encoding regions counted in step (C).

16. The method of claim 1 wherein said high throughput sequencing is sequencing by synthesis.

17. The method of claim 1 wherein the single PCR uses a plurality of V-segment oligonucleotide primers, each V-segment oligonucleotide primer capable of hybridizing to one or more TCRβ

V-regions or one or more Ig V-regions of said plurality of gene segments; and

a plurality of J segment oligonucleotide primers, each J-segment primer capable of hybridizing to one or more TCRβ

J-regions or one or more Ig J-regions of said plurality of gene segments.

18. The method of claim 17, wherein said plurality of V segment oligonucleotide primers are complementary to at least one TCR Vβ

-encoding gene segment.

19. The method of claim 17, wherein said plurality of J-segment oligonucleotide primers are complementary to at least one functional TCR Jβ

-encoding gene segment.

20. The method of claim 17 wherein said plurality of said template oligonucleotides is greater than or equal to the lesser of said plurality of said V-segment oligonucleotide primers and said plurality of J-segment oligonucleotide primers.

21. The method of claim 17 wherein said template composition comprises at least one template oligonucleotide amplified by each different pair of said V-segment oligonucleotide primers and said J-segment oligonucleotide primers.